Moreover, a synthesized USP8 inhibitor, 9-Ethyloxyimino-9H-indeno [1,2-b] pyrazine2,3-dicarbonitrile, has been shown to suppress multiple RTKs in gefitinib-resistant NSCLC cells. This evidence concerns the gene USP8 and non-small cell lung carcinoma.